FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF V600E Mutation By Ogkologos - March 11, 2026 349 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BREAKWATER study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Breast Cancer Survivor And Teenage Son Hand-Sew Neck Pillows To Bring... August 15, 2019 FDA Approval of KRAS Inhibitor Sotorasib for Lung Cancer Hailed as... June 25, 2021 Mom Gives Birth and Receives a Breast Cancer Diagnosis on the... September 23, 2020 Trial Establishes Preferred Treatment for Some People with Esophageal Cancer July 9, 2024 Load more HOT NEWS Asciminib Shows Superior Efficacy Over Investigator-Selected TKIs and Imatinib in Patients... Fostering Black leadership in cancer research This Breast Cancer Patient Is Using Boudoir Photography to Reclaim Her... Neoadjuvant Chemoimmunotherapy Superior to Neoadjuvant Chemotherapy with Event-Free Survival Benefit in...
